will enhance their appeal and universality without compromising the importance of MIQE as a set of standards that is beginning to achieve acceptance in the scientific community.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:

Employment or Leadership: C.T. Wittwer, Idaho Technology and Clinical Chemistry, AACC.

Consultant or Advisory Role: G.L. Shipley, Applied Biosystems.

Stock Ownership: None declared.

Honoraria: None declared.

Research Funding: C.T. Wittwer, Idaho Technology.

Expert Testimony: None declared.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.

References


Stephen A. Bustin2*
Vladimir Benes3
Jeremy A. Garson4
Jan Hellemans5,6
Jim Huggett7,8
Mikael Kubista9,10

2 Barts and the London School of Medicine and Dentistry
Queen Mary University of London
London, UK
3 EMBL GeneCore
Heidelberg, Germany
4 Centre for Virology
Research Department of Infection
University College Medical School
London, UK
5 Centre for Medical Genetics Ghent
Ghent University Hospital
Ghent University
Gent, Belgium
6 Biogazelle
Zwijnaarde, Belgium
7 LGC
Teddington, UK
8 Centre for Infectious Diseases
University College London
London, UK
9 TATAA Biocenter
Gothenburg, Sweden
10 Institute of Biotechnology
Czech Academy of Sciences
Prague, Czech Republic
11 Sequenom
San Diego, CA
12 Sigma-Aldrich
Haverhill, UK
13 Physiology Weihenstephan
Life Science Center Weihenstephan
TUM
Munich, Germany
14 University of Texas Health Science Center
at Houston
Houston, TX
15 Department of Pathology
University of Utah
Salt Lake City, UT
16 ARUP Institute for Clinical and Experimental Pathology
Salt Lake City, UT

*Address correspondence to this author at:
3rd Floor Alexandra Wing
The Royal London Hospital
London E1 1BB, UK
Fax +44-0-20-7377-7283
E-mail s.a.bustin@qmul.ac.uk

Previously published online at DOI: 10.1373/clinchem.2011.162958

Transferrin Saturation and Mortality

To the Editor:

Ellervik and colleagues (1) recently reported a positive association between transferrin saturation (TS) and mortality. Several questions arise from this observation: Is the association due to all causes of iron overload or to hereditary hemochromatosis only? Does the study underestimate the true association? And, is mortality due to variation in iron, transferrin, or both?

We have relevant data from population-based studies of twins and families of European descent living in Australia (2, 3). TS values (calculated from serum transferrin and iron) and HFE (hemochromatosis) genotypes for C282Y (rs1800562, genotyped) and H63D (rs1799945, imputed) are available for 8096 adults (3151 men and 4945 women; mean age, 47 years). Repeat TS measurements are available for 460 participants (178 men and 282 women) from studies in 1993–1996 and 2001–2005. Their mean age at the time of the second study was 50 years (range, 39–72 years).

The Discussion in the Ellervik et al. report implies that the association of TS with mortality is driven by the C282Y variant (which is associated with hemochromatosis) and that TS is acting as a surrogate for this variant. There is a lack of equivalence between TS values >50% and HFE variants, however. Table 1 shows the relationships between TS and genotype for the 288 participants for whom TS values
were ≥50% and both genotypes were available. Although just over half of the people with the YY genotype have a TS value ≥50%, only a minority of people with a TS value ≥50% are YY (about 10% for men and 20% for women). About a third of those with an increased TS are homozygous for the common allele. The inference that the relationship between TS and mortality is due to clinically unexpressed hemochromatosis needs further support before it can be accepted; high iron availability from any cause may be harmful. The situation is further complicated by the multiple effects of the 282Y allele, which not only increases TS but also decreases LDL cholesterol (4). Thus, this variant could produce adverse effects due to higher iron concentrations and beneficial effects due to lower LDL concentrations.

Second, an increased TS may contribute more to total mortality than this study indicates. As in many prospective studies, the predictor variable was measured only once; consequently, no allowance was made for the regression dilution effect caused by analytical and biological variation. As these authors point out, measurement errors and within-person variation in a risk factor study will produce a bias toward the null—that is, the size of the effect is underestimated. The degree of underestimation can be assessed from measurements taken on 2 occasions, either on the original cohort or with data from comparable groups. We found a significant but low 9-year- repeatability for TS: r = 0.30 (n = 178; P = <0.0001; 95% CI, 0.16–0.43) for men, and r = 0.33 (n = 282; P = <0.0001; 95% CI, 0.23–0.43) for women. Therefore, the necessary adjustment [A = 1/(1-r) (5)] is approximately 3. The concordance for high TS values was poor, because only 3 people had TS values ≥50% on both occasions. An assessment of the true odds ratio is complicated by the binary classification of the TS results, but the effect of the long-term mean TS on mortality will be substantially greater than the initial estimate—possibly 3 times as great.

Third, TS is a derived variable, so the association with mortality may be with iron, transferrin, or possibly both, but in opposite directions. It would be interesting if the authors could reanalyze their data to test whether iron and transferrin are predictors of mortality.

Our data and conclusions are subject to some limitations. There are differences between Australia and Denmark that have the potential to affect either the relationships between high TS and HFE genotypes or the repeatability of TS (and therefore the regression dilution factor). Additionally, how the regression dilution factor applies to dichotomous data is not clear, although it is applicable to survival and logistic regression as well as to bivariate quantitative data (5).

The points made with respect to TS apply to other existing or proposed risk factors. The choice between quantitative measurements and genotyping is important and will have to be made on a case-by-case basis as our knowledge of the effects of single-nucleotide polymorphisms on risk and risk factors increases. Quantitative risk factors are subject to analytical and biological variation, which can lead to underestimation of their contributions to risk. Methods exist to adjust for underestimation at an epidemiologic level, but they may not improve the detection of high-risk patients.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors’ Disclosures or Potential Conflicts of Interest: No authors declared any potential conflicts of interest.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.

References

Table 1. Percentages of individuals with TS values ≥50% by C282Y and H63D genotype, and of those with TS values ≥50% having each genotype.

<table>
<thead>
<tr>
<th>HFE genotype</th>
<th>Individuals with TS values ≥50% (by genotype), % (n)</th>
<th>Contribution of each genotype to the group with TS values ≥50%, % (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male Female Male Female</td>
<td></td>
</tr>
<tr>
<td>YY/HH</td>
<td>64.0 (16/25) 53.5 (23/43) 9.4 (16/171) 19.7 (23/117)</td>
<td></td>
</tr>
<tr>
<td>CY/HD</td>
<td>31.1 (23/74) 13.3 (16/120) 13.5 (23/171) 13.7 (16/117)</td>
<td></td>
</tr>
<tr>
<td>CC/DD</td>
<td>11.0 (8/73) 4.0 (4/101) 4.7 (8/171) 3.4 (4/117)</td>
<td></td>
</tr>
<tr>
<td>CY/HH</td>
<td>5.9 (22/370) 2.9 (16/561) 12.9 (22/171) 13.7 (16/117)</td>
<td></td>
</tr>
<tr>
<td>CC/HD</td>
<td>5.6 (39/696) 2.0 (22/1109) 22.8 (39/171) 18.8 (22/117)</td>
<td></td>
</tr>
<tr>
<td>CC/HH</td>
<td>3.3 (63/1913) 1.2 (36/3011) 36.8 (63/171) 30.8 (36/117)</td>
<td></td>
</tr>
</tbody>
</table>
In Reply

We thank Benyamin et al. for their response to our recent article (1). We are puzzled by their statement that our Discussion implies that the association of total mortality with increased transferrin saturation is driven by the C282Y/C282Y genotype. We intentionally did not write about genetic hemochromatosis in our paper; rather, our referral to “hemochromatosis” was meant to imply hemochromatosis by any cause, genetic or otherwise. The information regarding hemochromatosis genotypes, however, is available for the participants in both the Copenhagen City Heart Study and the Copenhagen General Population Study (2, 3). We have now calculated total mortality risks for both studies combined, as a function of hemochromatosis genotype vs wild type/wild type [design and statistics as described (1)]. These risks are: 1.2 (95% CI, 1.0–1.3) for C282Y/wild type; 0.8 (95% CI, 0.6–1.1) for C282Y/H63D; and 1.3 (95% CI, 0.7–2.4) for C282Y/C282Y. Thus, the increased association of total mortality with increased transferrin saturation that we noted was not driven mainly by hemochromatosis genotype.

We fully agree with the statement of Benyamin et al. regarding regression dilution bias (4) and originally considered correcting our results for this bias. For that purpose, we used measurements of transferrin saturation in the Copenhagen City Heart Study that we obtained for 4302 individuals on 2 examinations 10 years apart (1991–1994 and 2001–2003). The regression dilution factor we obtained (2.7) was used to correct total-mortality hazard ratios for transferrin saturation levels ≥50% vs levels <50%. We compared the corrected results with the uncorrected results from Table 2 in (1) for all sexes [corrected, 2.3 (95% CI, 1.5–3.7); uncorrected, 1.4 (95% CI, 1.2–1.6)], for men [corrected, 2.4 (95% CI, 1.4–4.7); uncorrected, 1.3 (95% CI, 1.1–1.6)], for women [corrected, 3.0 (95% CI, 1.7–6.5); uncorrected, 1.5 (95% CI, 1.1–2.0)], for the Copenhagen General Population Study [corrected, 4.9 (95% CI, 1.6–13); uncorrected, 1.8 (95% CI, 1.2–2.6)], and for the Copenhagen City Heart Study [corrected, 1.6 (95% CI, 1.0–2.5); uncorrected, 1.2 (95% CI, 1.0–1.4)].

![Fig. 1. Total mortality by stepwise increases in transferrin saturation (A), iron concentration (B), and transferrin concentration (C) in individuals in the general population.](image-url)

Results are shown for the Copenhagen General Population Study and the Copenhagen City Heart Study combined. Results for iron and transferrin concentration are shown by stepwise-increasing percentiles, similarly to transferrin saturation.

---

**Beben Benyamin**  
Grant W. Montgomery  
Nicholas G. Martin  
John B. Whitfield*  
Queensland Institute of Medical Research  
Royal Brisbane Hospital, Herston, Queensland, Australia

* Address correspondence to this author at:  
Genetic Epidemiology Unit  
Queensland Institute of Medical Research  
Locked Bag 2000  
Royal Brisbane Hospital, Herston  
Queensland 4029, Australia

Fax +61-7-3362-0101  
E-mail John.Whitfield@qimr.edu.au

Previously published online at  
DOI: 10.1373/clinchem.2011.162784